The role of CT10 regulation of kinase-like in cancer

Future Oncology

Volumn 10, Issue 16, 2014, Pages 2687-2697

  Guo, Chunmei ^a   Liu, Shuqing ^a   Sun, Ming Zhong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

biomarker; cancer; CRKL; invasion; metastasis

Indexed keywords

ADAPTOR PROTEIN; BIOLOGICAL MARKER; CT10 REGULATION OF KINASE LIKE PROTEIN; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; COLON CANCER; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NEUROBLASTOMA; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 84919829847     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.199     Document Type: Review

References (65)

1. Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene 20(44), 6348-6371 (2001).
2. Rodrigues SP, Fathers KE, Chan G et al. CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Mol. Cancer Res. 3(4), 183-194 (2005).
3. Prosser S, Sorokina E, Pratt P et al. CrkIII: A novel and biologically distinct member of the Crk family of adaptor proteins. Oncogene 22(31), 4799-4806 (2003).
4. Bell ES, Park M. Models of crk adaptor proteins in cancer. Genes Cancer 3(5-6), 341-352 (2013).
5. Watanabe T, Tsuda M, Makino Y et al. Crk adaptor protein-induced phosphorylation of Gab1 on tyrosine 307 via Src is important for organization of focal adhesions and enhanced cell migration. Cell Res. 19(5), 638-650 (2009).
6. Hossain S, Dubielecka PM, Sikorski AF et al. Crk and ABI1: Binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton. Genes Cancer 3(5-6), 402-413 (2012).
7. Kumar S, Fajardo JE, Birge RB et al. Crk at the quarter century mark: Perspectives in signaling and cancer. J. Cell Biochem. 115(5), 819-825 (2014).
8. Birge RB, Kalodimos C, Inagaki F et al. Crk and CrkL adaptor proteins: Networks for physiological and pathological signaling. Cell Commun. Signal. 7, 13 (2009).
9. Dai Y, Qi L, Zhang X et al. CrkI and p130(Cas) complex regulates the migration and invasion of prostate cancer cells. Cell Biochem. Funct. 29(8), 625-629 (2011).
10. Iwahara T, Akagi T, Shishido T et al. CrkII induces serum response factor activation and cellular transformation through its function in Rho activation. Oncogene 22(38), 5946-5957 (2003).
11. Tsuda M, Makino Y, Iwahara T et al. Crk associates with ERM proteins and promotes cell motility toward hyaluronic acid. J. Biol. Chem. 279(45), 46843-46850 (2004).
12. Brabek J, Constancio SS, Siesser PF et al. Crk-Associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-Transformed cells. Mol. Cancer Res. 3(6), 307-315 (2005).
13. Takino T, Nakada M, Miyamori H et al. CrkI adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res. 63(9), 2335-2337 (2003).
14. Mortazavi F, Dubinett S, Rettig M. c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells. Clin. Exp. Metastasis 28(4), 391-404 (2011).
15. Johnson KJ, Griswold IJ, O'Hare T et al. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. PLoS ONE 4(10), e7439 (2009).
16. Tsuda M, Tanaka S. Roles for crk in cancer metastasis and invasion. Genes Cancer 3(5-6), 334-340 (2012).
17. Sriram G, Birge RB. emerging roles for crk in human cancer. Genes Cancer 1(11), 1132-1139 (2011).
18. Natsume H, Shinmura K, Tao H et al. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J. Transl. Med. 3, 97-107 (2012).
19. Wang J, Chen X, Li P et al. CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126. Chem. Biol. Interact. 206(2), 230-238 (2013).
20. Lv S, Qin J, Yi R et al. CrkL efficiently mediates cell proliferation, migration, and invasion induced by TGF-beta pathway in glioblastoma. J. Mol. Neurosci. 51(3), 1046-1051 (2013).
21. Arai A, Aoki M, Weihua Y et al. CrkL plays a role in SDF-1-induced activation of the Raf-1/ MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells. Cell Signal. 18(12), 2162-2171 (2006).
22. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 19(23), 2783-2810 (2005).
23. Matsuura I, Denissova NG, Wang G et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430(6996), 226-231 (2004).
24. Liu CH, Chen TC, Chau GY et al. Analysis of protein-protein interactions in cross-Talk pathways reveals CRKL protein as novel prognostic marker in hepatocellular carcinoma. Mol. Cell. Proteomics 12(5), 1335-1349 (2013).
25. Liu CH, Chen TC, Chen CH et al. Differential network biology reveals a positive correlation between a novel protein-protein interaction and cancer cells migration. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2013, 2700-2703 (2013).
26. Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069), 820-827 (2005).
27. Ni QF, Tian Y, Tao JQ et al. Experimental study on CRKL promotes cellular proliferation of hepatocellular carcinoma. Chin. J. Clinicians 7(16), 7467-7470 (2013).
28. Han B, Luan L, Xu ZQ et al. Clinical significance and biological roles of CRKL in human bladder carcinoma. Tumour Biol. 35(5), 4101-4106 (2013).
29. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 98(5), 629-635 (2007).
30. Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem. Soc. Trans. 38(Pt 1), 217-222 (2010).
31. Xu YY, Mao XY, Song YX et al. Midkine confers adriamycin resistance in human gastric cancer cells. Tumour Biol. 33(5), 1543-1548 (2012).
32. Lee EJ, Lee SJ, Kim S et al. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-kappaB/AP-1 pathway: Involvement of the p21WAF1 expression. Cell Signal. 25(10), 2025-2038 (2013).
33. Yang C, Klein EA, Assoian RK et al. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. Biochem. J. 410(1), 167-175 (2008).
34. Dong QZ, Wang Y, Tang ZP et al. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am. J. Pathol. 182(3), 954-964 (2013).
35. Knudsen KE, Diehl JA, Haiman CA et al. Cyclin D1: Polymorphism, aberrant splicing and cancer risk. Oncogene 25 (11), 1620-1628 (2006).
36. Wang Y, Dong QZ, Fu L et al. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol. Carcinog. 52(11), 890-899 (2013).
37. Lin F, Chengyao X, Qingchang L et al. CRKL promotes lung cancer cell invasion through ERK-MMP9 pathway. Mol. Carcinog. doi:10.1002/mc.22148. (2014) (Epub ahead of print).
38. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 15(16), 718-727 (2006).
39. Ratschiller D, Heighway J, Gugger M et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smok-ing and predicts survival. J. Clin. Oncol. 21(11), 2085-2093 (2003).
40. Kim YH, Kwei KA, Girard L et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene 29(10), 1421-1430 (2010).
41. Cheung HW, Du J, Boehm JS et al. Amplification of CRKL induces transformation and EGFR inhibitor resistance in human non-small-cell lung cancers. Cancer Discov. 1(7), 608-625 (2011).
42. Pendergast AM, Quilliam LA, Cripe LD et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75(1), 175-185 (1993).
43. Schonherr C, Yang HL, Vigny M et al. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells. Oncogene 29(19), 2817-2830 (2010).
44. Ladanyi M. CRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: Is it all that it is cracked up to be? Cancer Discov. 1(7), 560-561 (2011).
45. Lan B Zhang j, Shan JX et al. Downregulation of CRKL expression can inhibit tumorigenesis in colon cancer. Front. Biosci. 19, 528-534 (2014).
46. Shen TM, Zhao CQ, Zhao Y et al. Crk and CrkL expression in epithelial ovarian carcinoma and the significance. Chin. General Practice 11(6), 940-942 (2008).
47. Wang J, Che YL, Li G et al. Crk and CrkL present with different expression and significance in epithelial ovarian carcinoma. Mol. Carcinog. 50(7), 506-515 (2011).
48. ten Hoeve J, Kaartinen V, Fioretos T et al. Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res. 54(10), 2563-2567 (1994).
49. Nichols GL, Raines MA, Vera JC et al. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 84(9), 2912-2918 (1994).
50. Singer CF, Hudelist G, Lamm W et al. Active (p)CrkL is overexpressed in human malignancies: Potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol. Rep. 15(2), 353-359 (2006).
51. Salgia R, Uemura N, Okuda K et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J. Biol. Chem. 270(49), 29145-29150 (1995).
52. ten Hoeve J, Arlinghaus RB, Guo JQ et al. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 84(6), 1731-1736 (1994).
53. Xu JP, Hu JD, Lin MH et al. Up-regulation of stathmin and CrkL protein expressions in adriamycin-resistant leukemia cell line K562/A02. J. Exp. Hemato. 19(6), 1383-1387 (2011).
54. Wang SS, Bing Z, Huang GS et al. Effect of CRKL gene expression on cell proliferation in K562 celI line. J. Fourth MiI. Med. Univ. 22(10), 878-880 (2001).
55. Vasconcelos FC, Nestal de Moraes G, Moellmann-Coelho A et al. Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients. Leuk. Res. 37(12), 1711-1718 (2013).
56. Zhao T, Miao Z, Wang Z et al. Overexpression of CRKL correlates with malignant cell proliferation in breast cancer. Tumour Biol. 34(5), 2891-2897 (2013).
57. Padmanabhan RA, Nirmala L, Murali M et al. CrkL is a co-Activator of estrogen receptor alpha that enhances tumorigenic potential in cancer. Mol. Endocrinol. 25(9), 1499-1512 (2011).
58. Zhang EY, Cristofanilli M, Robertson F et al. Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. J. Proteome Res. 12(6), 2805-2817 (2013).
59. Lamorte L, Royal I, Naujokas M et al. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol. Biol. Cell 13(5), 1449-1461 (2002).
60. Yanagi H, Wang L, Nishihara H et al. CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion. Biochem. Biophys. Res. Commun. 418(1), 104-109 (2012).
61. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350(19), 1937-1944 (2004).
62. Reedquist KA, Ross E, Koop EA et al. The small GTPase, Rap1, mediates CD31-induced integrin adhesion. J. Cell Biol. 148(6), 1151-1158 (2000).
63. Oberlin O, Rey A, Lyden E et al. Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from United States and European cooperative groups. J. Clin. Oncol. 26(14), 2384-2389 (2008).
64. Yeung CL, Ngo VN, Grohar PJ et al. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene 32(47), 5429-5438 (2013).
65. Graf R, Barbero S, Keller N et al. Src-inducible association of CrkL with procaspase-8 promotes cell migration. Cell Adh. Migr. 7(4), 362-369 (2013).